Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study.
COVID-19
Hospital acquired infection
Multi drug resistant
SARS-CoV-2 pandemic
bloodstream infections
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
21
04
2021
revised:
21
07
2021
accepted:
27
07
2021
pubmed:
21
8
2021
medline:
8
10
2021
entrez:
20
8
2021
Statut:
ppublish
Résumé
Correlation between coronavirus disease 2019 (COVID-19) and superinfections has been investigated, but remains to be fully assessed. This multi-centre study reports the impact of the pandemic on bloodstream infections (BSIs). This study included all patients with BSIs admitted to four Italian hospitals between 1 January and 30 June 2020. Clinical, demographic and microbiologic data were compared with data for patients hospitalized during the same period in 2019. Among 26,012 patients admitted between 1 January and 30 June 2020, 1182 had COVID-19. Among the patients with COVID-19, 107 BSIs were observed, with an incidence rate of 8.19 episodes per 1000 patient-days. The incidence of BSI was significantly higher in these patients compared with patients without COVID-19 (2.72/1000 patient-days) and patients admitted in 2019 (2.76/1000 patient-days). In comparison with patients without COVID-19, BSI onset in patients with COVID-19 was delayed during the course of hospitalization (16.0 vs 5 days, respectively). Thirty-day mortality among patients with COVID-19 was 40.2%, which was significantly higher compared with patients without COVID-19 (23.7%). BSIs in patients with COVID-19 were frequently caused by multi-drug-resistant pathogens, which were often centre-dependent. BSIs are a common secondary infection in patients with COVID-19, characterized by increased risk during hospitalization and potentially burdened with high mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Correlation between coronavirus disease 2019 (COVID-19) and superinfections has been investigated, but remains to be fully assessed. This multi-centre study reports the impact of the pandemic on bloodstream infections (BSIs).
METHODS
METHODS
This study included all patients with BSIs admitted to four Italian hospitals between 1 January and 30 June 2020. Clinical, demographic and microbiologic data were compared with data for patients hospitalized during the same period in 2019.
RESULTS
RESULTS
Among 26,012 patients admitted between 1 January and 30 June 2020, 1182 had COVID-19. Among the patients with COVID-19, 107 BSIs were observed, with an incidence rate of 8.19 episodes per 1000 patient-days. The incidence of BSI was significantly higher in these patients compared with patients without COVID-19 (2.72/1000 patient-days) and patients admitted in 2019 (2.76/1000 patient-days). In comparison with patients without COVID-19, BSI onset in patients with COVID-19 was delayed during the course of hospitalization (16.0 vs 5 days, respectively). Thirty-day mortality among patients with COVID-19 was 40.2%, which was significantly higher compared with patients without COVID-19 (23.7%). BSIs in patients with COVID-19 were frequently caused by multi-drug-resistant pathogens, which were often centre-dependent.
CONCLUSIONS
CONCLUSIONS
BSIs are a common secondary infection in patients with COVID-19, characterized by increased risk during hospitalization and potentially burdened with high mortality.
Identifiants
pubmed: 34416402
pii: S1201-9712(21)00623-8
doi: 10.1016/j.ijid.2021.07.065
pmc: PMC8372445
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-36Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None declared.
Références
Eur J Clin Invest. 2020 Oct;50(10):e13319
pubmed: 32535894
Lancet Glob Health. 2020 Apr;8(4):e480
pubmed: 32109372
Intensive Care Med. 2021 Feb;47(2):180-187
pubmed: 33506379
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Glob Antimicrob Resist. 2020 Jun;21:22-27
pubmed: 32156648
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Virus Res. 2020 Sep;286:198103
pubmed: 32717345
Clin Infect Dis. 2021 May 18;72(10):e533-e541
pubmed: 32820807
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
Infect Dis (Lond). 2020 Nov - Dec;52(12):919-922
pubmed: 32779951
Appl Microbiol Biotechnol. 2020 Sep;104(18):7777-7785
pubmed: 32780290
Virus Res. 2020 Aug;285:198018
pubmed: 32430279
Clin Microbiol Infect. 2021 Mar;27(3):451-457
pubmed: 33223114
Front Microbiol. 2017 Jun 23;8:1041
pubmed: 28690590
EMBO Mol Med. 2020 Jul 7;12(7):e12560
pubmed: 32453917
Int J Biol Sci. 2020 Jul 9;16(14):2479-2489
pubmed: 32792851
Anaesthesia. 2020 Jul;75(7):928-934
pubmed: 32246838
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Intensive Care Med. 2020 Feb;46(2):266-284
pubmed: 32047941
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Infect Immun. 2015 Oct;83(10):3764-70
pubmed: 26216421
J Antimicrob Chemother. 2020 Nov 1;75(11):3359-3365
pubmed: 32829390
Cell Rep. 2021 Jan 5;34(1):108590
pubmed: 33357411
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
JAMA. 2013 Jan 16;309(3):275-82
pubmed: 23321766
Intensive Care Med. 2020 Nov;46(11):2071-2074
pubmed: 32902729
J Infect Dis. 2011 Jun 15;203(12):1739-47
pubmed: 21606532
Epidemiol Infect. 2004 Jun;132(3):407-8
pubmed: 15188709
PLoS One. 2021 Jan 28;16(1):e0246170
pubmed: 33507954
Gastroenterology. 2020 Sep;159(3):944-955.e8
pubmed: 32442562
Clin Infect Dis. 2020 Jul 28;:
pubmed: 32719848
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
QJM. 2020 Aug 1;113(8):546-550
pubmed: 32569363
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Cell Microbiol. 2018 Dec;20(12):e12966
pubmed: 30329198